Trial Profile
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 06 Feb 2024 Planned End Date changed from 2 Apr 2024 to 22 Sep 2024.
- 04 Apr 2023 Planned End Date changed from 1 Nov 2023 to 2 Apr 2024.
- 03 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.